Business
First day of dealings on AIM
First day of dealings on AIM.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 2289O OptiBiotix Health PLC 05 August 2014 \n \n\nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nFirst day of dealings on AIM\n \nOptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its admission to trading on AIM at 8.00am today. Dealings in the Company's ordinary shares will commence under the AIM trading symbol OPTI.\n \nSummary\n· OptiBiotix Health plc develops compounds which modify the human microbiome - the collective genome of\n the microbes in the body - to prevent and manage human disease\n· The Company has raised £3.3m (before expenses) by way of a placing at a price of 8p per share\n· The funds will be used:\n- to develop the intellectual property of OptiBiotix;\n- to commercialise OptiBiotix products; and\n- for general working capital purposes\n· The issued share capital of the Company on Admission comprises 71,754,534 new ordinary shares of 2 pence\n each, giving the Company a market capitalisation of approximately £6 million\n· Cairn Financial Advisers is the Company's nominated adviser; Peterhouse Corporate Finance is broker\n· OptiBiotix's AIM trading symbol is OPTI and ISIN code is GB00BP0RTP38 \n \nAbout OptiBiotix - www.optibiotix.com\nOptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.\n \nThe aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.\n \nOptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform te...